1-2 of 2
Mary Tagliaferri
Close
Sort by
Journal Articles

A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia

Clinical Trials & Observations
Hrishikesh Krishna Srinagesh, Clayton Jackson, Parveen Shiraz, Nikeshan Jeyakumar, Mark P Hamilton, Emily Egeler, Sharon Mavroukakis, Adam Kuo, Juancarlos Cancilla, Bita Sahaf, Neha Agarwal, Alyssa M Kanegai, Anne Marijn Kramer, Sally Arai, Sushma Bharadwaj, Saurabh Dahiya, Hitomi Hosoya, Laura J Johnston, Vanessa E Kennedy, Michaela Liedtke, Robert Lowsky, Lekha Mikkilineni, Robert S. Negrin, Andrew R. Rezvani, Surbhi Sidana, Judith A. Shizuru, Melody Smith, Wen-Kai Weng, Steven A Feldman, Matthew J. Frank, Zachary Lee, Mary Tagliaferri, A Mario Q. Marcondes, David B Miklos, Crystal L. Mackall, Lori Muffly
Journal: Blood
Blood blood.2024024952.
https://doi.org/10.1182/blood.2024024952
Published: 2024
Includes: Supplemental data
Journal Articles

A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in Combination with Daratumumab As a Salvage Regimen for Multiple Myeloma

Nina D. Shah, MD, Cameron J. Turtle, MBBS, PhD, Andrew J. Cowan, MD, Julio C. Chavez, MD, Lihua E Budde, MD PhD, Mario Q. Marcondes, MD PhD, Zachary Lee, PharmD, Wei Lin, MD, Jonathan Zalevsky, Mary Tagliaferri, MD, Krina K. Patel, MDMSc
Journal: Blood
Blood (2019) 134 (Supplement_1): 4459.
https://doi.org/10.1182/blood-2019-122494
Published: 2019